Banzet P, Jacquillat C, Civatte J, Puissant A, Maral J, Chastang C, Israel L, Belaich S, Jourdain J C, Weil M, Auclerc G
Cancer. 1978 Apr;41(4):1240-8. doi: 10.1002/1097-0142(197804)41:4<1240::aid-cncr2820410404>3.0.co;2-j.
In a prospective randomized study, the effect of chemotherapy (either systemic or combined intraarterial and systemic) was studied in 117 patients undergoing a curative resection of Clark's level III, IV or V malignant melanoma. Systemic chemotherapy was started one month after surgery one week courses with an I.V. injection of Vinblastin 6 mg/m2, Thiotepa 6 mg/m2, Rufocromomycine 60 microgram/m2, Methotrexate 15 mg/m2 on day one with procarbazine 30 mg/m2 orally daily were given every other week for three months and later every four weeks. Intraarterial chemotherapy of DTIC 80 mg/kg day for ten days was given 28 days prior to surgery. 65 patients with limb malignant melanoma were treated either by surgery only (27 patients), or by systemic chemotherapy (23 patients) or by preoperative intraarterial chemotherapy and systemic chemotherapy (15 patients): 52 patients with non limb malignant melanoma were treated either by surgery only (28 patients) or by systemic chemotherapy (24 patients). We drew curves of disease free survival following surgery and studied the levelling off of the curves, 24 months after surgery 65% of the patients treated by surgery alone were alive and free of disease whereas 81% of the patients treated by surgery and chemotherapy were alive and free of disease (p less than 0.05) suggesting a possible benefit of adjuvant chemotherapy. Intraarterial preoperative chemotherapy has not proved of additional benefit to date.
在一项前瞻性随机研究中，对117例接受Clark III、IV或V级恶性黑色素瘤根治性切除术的患者，研究了化疗（全身化疗或动脉内与全身联合化疗）的效果。全身化疗在术后1个月开始，采用静脉注射长春碱6mg/m²、噻替派6mg/m²、链黑霉素60μg/m²、甲氨蝶呤15mg/m²，第1天口服丙卡巴肼30mg/m²，每两周进行1周疗程，共3个月，之后每4周进行1次。术前28天给予动脉内化疗，用达卡巴嗪80mg/kg，持续10天。65例肢体恶性黑色素瘤患者，分别接受单纯手术治疗（27例）、全身化疗（23例）或术前动脉内化疗与全身化疗（15例）；52例非肢体恶性黑色素瘤患者，分别接受单纯手术治疗（28例）或全身化疗（24例）。我们绘制了术后无病生存曲线，并研究曲线的平稳情况，术后24个月，单纯手术治疗的患者中65%存活且无疾病，而接受手术和化疗的患者中81%存活且无疾病（p<0.05），提示辅助化疗可能有益。迄今为止，术前动脉内化疗尚未证明有额外益处。
